The shares of biosensor diagnostic technology company GBS’s (GBS) have slumped more than 50% in price this year, reflecting investors’ pessimism. The company’s weak financial position seems to be overshadowing…
The shares of biosensor diagnostic technology company GBS’s (GBS) have slumped more than 50% in price this year, reflecting investors’ pessimism. The company’s weak financial position seems to be overshadowing…